Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02645032
Other study ID # IVI T001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 19, 2016
Est. completion date February 9, 2017

Study information

Verified date February 2018
Source International Vaccine Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I, Randomized, observer-blinded, age de-escalating study.

The study objectives are:

1. To evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks.

2. To assess the immunogenicity of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks.

3. To compare the safety and immunogenicity of Vi-DT and Vi-Polysaccharide typhoid vaccines.


Description:

This study will be carried out in healthy adults and children at a single site. Subjects will be stratified according to age.

The study procedure is as follows:

Visit 1 (day-1 to -7): Screen participants by medical history, physical examination and lab investigations. Collect blood for safety and immunogenicity assessments.

Visit 2 (day 0): Enroll, randomize and administer first dose of vaccine to eligible participants

Visit 3 (day 3): Assess participant safety by medical history and physical examination

Visit 4 (day 7): Record solicited adverse reaction 7 days post vaccination, and collect blood for safety lab assessments.

Visit 5 (day 28): Assess participant safety, collect blood for immunogenicity assessments, and administer second vaccine dose

Visit 6 (day 31): Participants safety will be assessed by medical history and physical examination

Visit 7 (day 35): Record solicited adverse reaction 7 days post second vaccination.

Visit 8 (day 56): Collect blood for immunogenicity assessments, assess participant safety, and fill in study completion form in the absence of any safety concern.

This study is observer-blind: vaccine administrator and vaccine safety evaluator will be two distinct persons to avoid bias of safety assessment. Trial staff other than the vaccine administrator.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date February 9, 2017
Est. primary completion date February 9, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years to 45 Years
Eligibility Inclusion Criteria:

1. Healthy male and female individual 2-45 years of age

2. Participants/Parents who have voluntarily given informed consent and/or assent.

3. Participants/Parents willing to commit complying with the study procedures of the investigator and available for the entire duration of study

Exclusion Criteria:

1. Participants concomitantly enrolled or scheduled to be enrolled in another trial

2. Acute illness, in particular infectious diseases or fever (axillary temperature > 38°C), with in three days prior to enrollment and vaccination.

3. Known history of allergy to vaccines or other medications

4. Known history of allergy to egg, chiken protein, neomycin and formaldehyde.

5. History of uncontrolled coagulopathy or blood disorders

6. Known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (> 20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs

7. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives

8. Pregnancy & Lactation (female adults)

9. Female with child-bearing potential during the study period. i.e., sexually active and not practicing effective acceptable contraceptive method

10. Individuals who have previously received any vaccines against typhoid fever

11. Individuals already immunized with any licensed vaccine within 4 weeks prior to enrolment/vaccination (day 0) and expected to receive other licensed vaccines within 60 days following the first dose (day 0), except for tetanus toxoid vaccine

12. Individuals who have a previously ascertained or suspected disease caused by S. typhi.

13. Individuals who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. typhi

14. History of alcohol or substance abuse

15. Subject planning to move from the study area before the end of study period

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Vi-DT
Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
Typhim Vi®
Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
VAXIGRIP®
Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose) *Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
International Vaccine Institute SK Chemicals Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Safety endpoints for solicited adverse events (reactogenicity) and serious adverse events Proportion of participants with local and systemic solicited adverse events (reactogenicity) and Proportion of participant with Serious Adverse Events (SAEs) 4 weeks post first and second vaccination
Secondary Proportion of participants with sero-conversion Defined as a four-fold rise in anti-Vi antibody titers compared to baseline measured by anti-Vi IgG ELISA and Serum Bactericidal Assay 4 weeks post first and second injections of Vi-DT and one injection of Vipolysaccharide
Secondary Geometric Mean Titers (GMT) Measurement of the Geometric Mean Titers (GMT) following 4 weeks post first and second injections of Vi-DT and one injection of Vi-polysaccharide vaccine 4 weeks post first and second vaccination
See also
  Status Clinical Trial Phase
Completed NCT03312699 - Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Phase 1
Completed NCT01405521 - Understanding Typhoid Disease After Vaccination Phase 2
Completed NCT00125047 - Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood Phase 4
Completed NCT00131833 - Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Phase 4
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT01466387 - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Phase 3
Active, not recruiting NCT03933098 - Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Phase 3
Completed NCT00679172 - Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults Phase 2
Completed NCT00125008 - Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Phase 4
Recruiting NCT04878549 - Transcriptomic Responses for the Identification of Pathogens
Recruiting NCT05475379 - Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Phase 1/Phase 2
Completed NCT04204096 - Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Phase 3
Active, not recruiting NCT03299426 - Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Phase 3
Completed NCT01019083 - Studies of Immune Responses to Orally Administered Vaccines in Developing Country Phase 1/Phase 2
Completed NCT03614533 - Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Phase 2
Completed NCT00131820 - Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Phase 4
Completed NCT03527355 - Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Phase 2

External Links